研究者
J-GLOBAL ID：202101016178776816   更新日: 2024年01月30日

舩越 慶

Funakoshi Kei
競争的資金等の研究課題 (3件)：
  • 2008 - 2009 自己免疫性ニューロパチーの新規標的分子同定と疾患モデル樹立
  • 2006 - 2007 Fisher症候群モデル動物の樹立
  • 2005 - 2006 1次感覚ニューロンにおけるb系列ガングリオシドの機能的役割
論文 (31件)：
  • Suzuki Keisuke, Suzuki Shiho, Shiina Tomohiko, Haruyama Yasuo, Fujita Hiroaki, Funakoshi Kei, Hirata Koichi. Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study. Journal of neurology. 2023
  • Funakoshi Kei, Suzuki Keisuke. A safe change from eculizumab to satralizumab in a patient with neuromyelitis optica spectrum disorder. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2022. 44. 3. 1097-1098
  • Komagamine Tomoko, Suzuki Keisuke, Kokubun Norito, Komagamine Junpei, Kawasaki Akiko, Funakoshi Kei, Hirata Koichi. Sleep-related hallucinations in patients with Parkinson's disease. PloS one. 2022. 17. 10. e0276736
  • Watanabe Shohei, Tokuhara Yusuke, Hiratsuka Mari, Yoshizumi Kazuki, Ukon Shinichiro, Kasama Shuhei, Takeda Masanaka, Funakoshi Kei, Kimura Takashi. Additional Steroid Therapy for Delayed Facial Palsy in Miller Fisher Syndrome. Internal medicine (Tokyo, Japan). 2022. 61. 22. 3435-3438
  • Suzuki Keisuke, Funakoshi Kei, Fujita Hiroaki, Hirata Koichi. The Effect of Rotigotine on Cognitive Function, Daytime Sleepiness, and Sleep Problems in Parkinson Disease: An Open-Label Pilot Study. Clinical neuropharmacology. 2022. 45. 3. 61-64
もっと見る
※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。 登録・更新については、こちらをご覧ください。

前のページに戻る

TOP

BOTTOM